Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with
cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of
pembrolizumab until disease progression or recurrence